作者:Anna Kryshchyshyn、Danylo Kaminskyy、Oleksandr Karpenko、Andrzej Gzella、Philippe Grellier、Roman Lesyk
DOI:10.1016/j.ejmech.2019.04.052
日期:2019.7
have been investigated as potent drugs for trypanosomiasis treatment, but no new drug has been marketed in the past 3 decades. 4-Thiazolidinone/thiazole as privileged structures and thiosemicarbazides cyclic analogs are well known scaffolds in novel antitrypanosomal agent design. We present here the design and synthesis of new hybrid molecules bearing thiazolidinone/thiazole cores linked by the hydrazone
已经研究了各种化合物作为治疗锥虫病的有效药物,但是在过去的30年中,没有新的药物上市。4-噻唑烷酮/噻唑作为优先结构和硫代氨基脲环类似物是新型抗锥虫药物设计中众所周知的支架。我们在这里介绍新的杂合分子的设计和合成,这些杂合分子带有由zo基与各种分子片段连接的噻唑烷酮/噻唑核。结构优化导致具有苯基吲哚或苯基咪唑并[2,1- b ] [1,3,4]噻二唑部分的化合物对布鲁氏锥虫和冈比亚锥虫具有优异的抗锥虫活性。生物学研究允许鉴定出亚微摩尔水平的IC 50,良好的选择性指数,对人原代成纤维细胞的相对较低的细胞毒性以及较低的急性毒性的化合物。